Bio Financial Statements From 2010 to 2025

BPTH Stock  USD 0.82  0.04  5.13%   
Bio Path financial statements provide useful quarterly and yearly information to potential Bio Path Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bio Path financial statements helps investors assess Bio Path's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bio Path's valuation are summarized below:
Market Capitalization
4.7 M
Earnings Share
(8.34)
We have found one hundred twenty available fundamental signals for Bio Path Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Bio Path Holdings prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year.

Bio Path Total Revenue

37,000

Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Path's main balance sheet or income statement drivers, such as Depreciation And Amortization of 174.9 K, Interest Expense of 31.2 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 472, Dividend Yield of 0.0 or PTB Ratio of 9.48. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
  
Check out the analysis of Bio Path Correlation against competitors.

Bio Path Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.5 M3.7 M9.5 M
Pretty Stable
Short and Long Term Debt Total175.6 K101.7 K319.2 K
Slightly volatile
Other Current Liabilities1.6 M1.5 M724.3 K
Slightly volatile
Total Current Liabilities2.3 M2.2 M1.1 M
Slightly volatile
Property Plant And Equipment Net344.7 K204.7 K312.2 K
Slightly volatile
Current Deferred Revenue10.3 K10.8 K12.8 K
Slightly volatile
Accounts Payable551.8 K525.5 K266.9 K
Slightly volatile
Cash1.1 M1.2 M7.2 M
Pretty Stable
Non Current Assets Total152.2 K160.2 K845.2 K
Slightly volatile
Cash And Short Term Investments1.1 M1.2 M7.2 M
Pretty Stable
Common Stock Shares Outstanding292.6 K549.7 K358.4 K
Slightly volatile
Liabilities And Stockholders Equity3.5 M3.7 M9.5 M
Pretty Stable
Non Current Liabilities Total1.1 MM503.3 K
Pretty Stable
Other Current Assets2.4 M2.3 M1.2 M
Slightly volatile
Other Stockholder Equity130.5 M124.3 M61.5 M
Slightly volatile
Total Liabilities3.4 M3.2 M1.5 M
Slightly volatile
Property Plant And Equipment Gross1.5 M1.4 M637.9 K
Slightly volatile
Total Current Assets3.3 M3.5 M8.7 M
Slightly volatile
Short Term Debt117.3 K92.7 K109.4 K
Slightly volatile
Intangible Assets1.3 M692.1 K1.1 M
Slightly volatile
Common Stock85590035.1 K
Slightly volatile
Common Stock Total Equity4.3 K4.5 K35.5 K
Slightly volatile
Capital Surpluse99.4 M94.6 M54.1 M
Slightly volatile
Other Liabilities2.3 M2.6 M2.9 M
Slightly volatile
Net Invested Capital481.8 K507.1 K8.9 M
Very volatile
Net Working Capital1.2 M1.3 M8.3 M
Very volatile
Capital Stock1.1 K1.1 K2.3 K
Slightly volatile
Capital Lease Obligations96.6 K101.7 K328 K
Slightly volatile

Bio Path Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization174.9 K94.3 K190.3 K
Very volatile
Selling General Administrative2.4 M4.7 MM
Slightly volatile
Other Operating Expenses19.1 M18.2 M8.8 M
Slightly volatile
Total Operating Expenses19.1 M18.2 M8.8 M
Slightly volatile
Research Development14 M13.3 M5.6 M
Slightly volatile
Non Operating Income Net Other28.4 K29.9 K248.7 K
Very volatile
Interest Income31 K59.8 K27.1 K
Slightly volatile
Net Interest Income32.5 K59.8 K25 K
Slightly volatile
Preferred Stock And Other Adjustments830.4 K934.2 KM
Slightly volatile
Reconciled Depreciation198.9 K164.7 K311.3 K
Slightly volatile
Non Recurring486.4 K547.2 K596.6 K
Slightly volatile
Selling And Marketing Expenses98.4 K110.7 K120.7 K
Slightly volatile

Bio Path Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.1 M11.9 M8.2 M
Slightly volatile
Depreciation179.9 K204.7 K203.6 K
Pretty Stable
Total Cash From Financing Activities2.4 M2.5 M6.8 M
Very volatile
End Period Cash Flow1.1 M1.2 M7.2 M
Pretty Stable
Change Receivables195.6 K220 K239.9 K
Slightly volatile
Stock Based Compensation531.6 K844.1 K448.5 K
Slightly volatile
Issuance Of Capital Stock2.9 M3.1 M4.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4724973.9 K
Slightly volatile
Days Sales Outstanding56.4287.791.1544
Very volatile
Average Payables69 K97.9 K101 K
Very volatile
Stock Based Compensation To Revenue44.9624.6540.1119
Slightly volatile
Capex To Depreciation0.10.110.5542
Slightly volatile
EV To Sales3343513.6 K
Slightly volatile
Inventory Turnover89.0344.66208
Slightly volatile
Days Of Inventory On Hand8.048.4613.6242
Slightly volatile
Payables Turnover0.430.451.8263
Slightly volatile
Sales General And Administrative To Revenue180110161
Slightly volatile
Average Inventory3.5 K2.1 K1.7 K
Very volatile
Research And Ddevelopement To Revenue313170279
Slightly volatile
Capex To Revenue13.7413.0913.4913
Slightly volatile
Cash Per Share1.881.98146
Slightly volatile
Days Payables Outstanding436843434
Slightly volatile
Income Quality0.660.650.8446
Pretty Stable
Intangibles To Total Assets0.09480.09980.2014
Slightly volatile
Current Ratio1.361.449.2286
Very volatile
Receivables Turnover6.194.314.1787
Very volatile
Graham Number28.8730.39675
Slightly volatile
Capex Per Share0.06310.06644.8356
Slightly volatile
Average Receivables115.5 K110 K114.1 K
Slightly volatile
Revenue Per Share1.61.691.8621
Slightly volatile
Interest Debt Per Share0.260.274.1188
Slightly volatile
Debt To Assets0.03830.04040.1019
Slightly volatile
Operating Cycle8.048.4616.6012
Slightly volatile
Days Of Payables Outstanding436843434
Slightly volatile
Ebt Per Ebit1.081.171.0023
Very volatile
Total Debt To Capitalization0.220.230.1725
Slightly volatile
Quick Ratio1.361.449.2175
Very volatile
Net Income Per E B T1.11.151.0091
Slightly volatile
Cash Ratio0.470.58.0577
Very volatile
Days Of Inventory Outstanding8.048.4613.6242
Slightly volatile
Days Of Sales Outstanding56.4287.791.1544
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.171.151.0454
Pretty Stable
Fixed Asset Turnover0.06180.06510.092
Slightly volatile
Debt Ratio0.03830.04040.1019
Slightly volatile
Price Sales Ratio4724973.9 K
Slightly volatile
Asset Turnover0.00460.00480.0358
Slightly volatile

Bio Path Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap18.4 M22.8 M23.9 M
Pretty Stable
Enterprise ValueM2.1 M5.3 M
Slightly volatile

Bio Fundamental Market Drivers

Cash And Short Term Investments1.1 M

Bio Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bio Path Financial Statements

Investors use fundamental indicators, such as Bio Path's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bio Path's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue10.8 K10.3 K
Cost Of Revenue204.7 K194.5 K
Stock Based Compensation To Revenue 24.65  44.96 
Sales General And Administrative To Revenue 109.50  179.88 
Research And Ddevelopement To Revenue 170.32  313.05 
Capex To Revenue 13.09  13.74 
Revenue Per Share 1.69  1.60 
Ebit Per Revenue(278.67)(292.61)

Currently Active Assets on Macroaxis

When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out the analysis of Bio Path Correlation against competitors.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.34)
Return On Assets
(1.40)
Return On Equity
(3.66)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.